News

- Proceeds support advancing clinical development of next-generation cancer immunotherapies targeting A2A adenosine receptor and anti-TIGIT immune checkpoint -

- Oversubscribed round co-led by new

As of February 21st, Prof. Etienne Sokal, M.D., Ph.D., has stepped back from his operational role as Group CMO and will transition to the position of Chairman of Promethera®’s Scientific & Medical

Belgian biotechnology company ViroVet announced today that it has made its expertise, research staff as well as part of its research facility available to support COVID19 research and sample testing

Initial clinical data expected in 1H 2021

Cambridge, MA and Gosselies, Belgium – February 27, 2020 – iTeos Therapeutics Inc., a privately-held clinical-stage biotechnology company developing

Belgium – 19 December 2019 – Syndesi Therapeutics SA, a clinical stage biotechnology company developing novel modulators of the synaptic vesicle protein SV2A for the treatment of cognitive impairment,

Total amount raised in the Series D reaches €47.2 Million.

Mont-Saint-Guibert, Belgium, and Tokyo, Japan, December 16, 2019 – Promethera® Biosciences SA, a global innovator in cell-based medicines

Study will evaluate the safety and efficacy of the combination of iTeos’ EOS100850 and Merck’s KEYTRUDA® (pembrolizumab)

Gosselies, Belgium and Cambridge, MA – Dec. 12, 2019 – iTeos Therapeutics

 - Bringing Innovative Liver-Focused Cell therapies to Japanese Markets -

Promethera® Biosciences SA (“Promethera®”) and MEDIPAL HOLDINGS CORPORATION (“MEDIPAL”) today announced that they have

Belgium – 5 November 2019 – Syndesi Therapeutics SA, a biotechnology company developing novel modulators of the synaptic vesicle protein SV2A for the treatment of cognitive impairment, today announced

Study highlights potential benefit in rare pediatric orthopedic disorder

Mont-Saint-Guibert, Belgium, October 2, 2019 : Novadip Biosciences (“Novadip” or “the company”), a clinical-stage